This HTML5 document contains 244 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n16http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/bindingdb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/kegg-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/pubchem-compound/
n7http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n4http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/kegg-drug/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/pubchem-substance/
n19http://linked.opendata.cz/resource/drugbank/dosage/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/drugbank/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/iuphar/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/guide-to-pharmacology/
n11http://bio2rdf.org/drugbank:
n18http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n9http://www.rxlist.com/cgi/generic/
n14http://linked.opendata.cz/resource/drugbank/patent/
n26http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n13http://www.drugs.com/cdi/
n27http://linked.opendata.cz/resource/drugbank/property/
n12http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n31http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/wikipedia/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00904/identifier/pharmgkb/
n32http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00904
rdf:type
n3:Drug
n3:description
A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties. [PubChem]
n3:dosage
n19:271B5CD3-363D-11E5-9242-09173F13E4C5 n19:271B5CCF-363D-11E5-9242-09173F13E4C5 n19:271B5CD0-363D-11E5-9242-09173F13E4C5 n19:271B5CD1-363D-11E5-9242-09173F13E4C5 n19:271B5CD2-363D-11E5-9242-09173F13E4C5 n19:271B5CD4-363D-11E5-9242-09173F13E4C5 n19:271B5CC4-363D-11E5-9242-09173F13E4C5 n19:271B5CC5-363D-11E5-9242-09173F13E4C5 n19:271B5CC6-363D-11E5-9242-09173F13E4C5 n19:271B5CC7-363D-11E5-9242-09173F13E4C5 n19:271B5CC8-363D-11E5-9242-09173F13E4C5 n19:271B5CC9-363D-11E5-9242-09173F13E4C5 n19:271B5CCA-363D-11E5-9242-09173F13E4C5 n19:271B5CCB-363D-11E5-9242-09173F13E4C5 n19:271B5CCC-363D-11E5-9242-09173F13E4C5 n19:271B5CCD-363D-11E5-9242-09173F13E4C5 n19:271B5CCE-363D-11E5-9242-09173F13E4C5 n19:271B5CD5-363D-11E5-9242-09173F13E4C5 n19:271B5CD6-363D-11E5-9242-09173F13E4C5 n19:271B5CD7-363D-11E5-9242-09173F13E4C5 n19:271B5CC3-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D: A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med. 2002 Apr;39(4):397-403. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11919526 # Yilmaz HL, Yildizdas RD, Sertdemir Y: Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children--a double-blind randomized study. Aliment Pharmacol Ther. 2010 Jan;31(1):82-91. Epub . "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19758398 # Gregory RE, Ettinger DS: 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs. 1998 Feb;55(2):173-89. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9506240 # Gan TJ: Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same? CNS Drugs. 2005;19(3):225-38. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15740177
n3:group
approved
n3:halfLife
5.7 hours
n3:indication
For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, postoperation, and radiation. Also used for the treatment of postoperative nausea and vomiting.
n3:manufacturer
n4:271B5C67-363D-11E5-9242-09173F13E4C5 n4:271B5C68-363D-11E5-9242-09173F13E4C5 n4:271B5C65-363D-11E5-9242-09173F13E4C5 n4:271B5C66-363D-11E5-9242-09173F13E4C5 n4:271B5C89-363D-11E5-9242-09173F13E4C5 n4:271B5C8A-363D-11E5-9242-09173F13E4C5 n4:271B5C87-363D-11E5-9242-09173F13E4C5 n4:271B5C88-363D-11E5-9242-09173F13E4C5 n4:271B5C85-363D-11E5-9242-09173F13E4C5 n4:271B5C86-363D-11E5-9242-09173F13E4C5 n4:271B5C70-363D-11E5-9242-09173F13E4C5 n4:271B5C71-363D-11E5-9242-09173F13E4C5 n4:271B5C6E-363D-11E5-9242-09173F13E4C5 n4:271B5C6F-363D-11E5-9242-09173F13E4C5 n4:271B5C6C-363D-11E5-9242-09173F13E4C5 n4:271B5C6D-363D-11E5-9242-09173F13E4C5 n4:271B5C78-363D-11E5-9242-09173F13E4C5 n4:271B5C84-363D-11E5-9242-09173F13E4C5 n4:271B5C79-363D-11E5-9242-09173F13E4C5 n4:271B5C76-363D-11E5-9242-09173F13E4C5 n4:271B5C77-363D-11E5-9242-09173F13E4C5 n4:271B5C83-363D-11E5-9242-09173F13E4C5 n4:271B5C74-363D-11E5-9242-09173F13E4C5 n4:271B5C75-363D-11E5-9242-09173F13E4C5 n4:271B5C72-363D-11E5-9242-09173F13E4C5 n4:271B5C73-363D-11E5-9242-09173F13E4C5 n4:271B5C81-363D-11E5-9242-09173F13E4C5 n4:271B5C82-363D-11E5-9242-09173F13E4C5 n4:271B5C7F-363D-11E5-9242-09173F13E4C5 n4:271B5C80-363D-11E5-9242-09173F13E4C5 n4:271B5C7D-363D-11E5-9242-09173F13E4C5 n4:271B5C7E-363D-11E5-9242-09173F13E4C5 n4:271B5C7B-363D-11E5-9242-09173F13E4C5 n4:271B5C7C-363D-11E5-9242-09173F13E4C5 n4:271B5C6B-363D-11E5-9242-09173F13E4C5 n4:271B5C7A-363D-11E5-9242-09173F13E4C5 n4:271B5C69-363D-11E5-9242-09173F13E4C5 n4:271B5C6A-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00904 n26:DB00904
dcterms:title
Ondansetron
adms:identifier
n16:50000493 n17:4434 n18:0338-1762-41 n20:4595 n21:C07325 n22:D00456 n23:2290 n24:2290 n25:DB00904 n29:46504819 n30:PA450705 n31:Ondansetron
n3:mechanismOfAction
Ondansetron is a selective serotonin 5-HT<sub>3</sub> receptor antagonist. The antiemetic activity of the drug is brought about through the inhibition of 5-HT<sub>3</sub> receptors present both centrally (medullary chemoreceptor zone) and peripherally (GI tract). This inhibition of 5-HT<sub>3</sub> receptors in turn inhibits the visceral afferent stimulation of the vomiting center, likely indirectly at the level of the area postrema, as well as through direct inhibition of serotonin activity within the area postrema and the chemoreceptor trigger zone.
n3:packager
n4:271B5C47-363D-11E5-9242-09173F13E4C5 n4:271B5C5E-363D-11E5-9242-09173F13E4C5 n4:271B5C5F-363D-11E5-9242-09173F13E4C5 n4:271B5C5C-363D-11E5-9242-09173F13E4C5 n4:271B5C5D-363D-11E5-9242-09173F13E4C5 n4:271B5C28-363D-11E5-9242-09173F13E4C5 n4:271B5C5B-363D-11E5-9242-09173F13E4C5 n4:271B5C50-363D-11E5-9242-09173F13E4C5 n4:271B5C51-363D-11E5-9242-09173F13E4C5 n4:271B5C4E-363D-11E5-9242-09173F13E4C5 n4:271B5C4F-363D-11E5-9242-09173F13E4C5 n4:271B5C54-363D-11E5-9242-09173F13E4C5 n4:271B5C55-363D-11E5-9242-09173F13E4C5 n4:271B5C52-363D-11E5-9242-09173F13E4C5 n4:271B5C53-363D-11E5-9242-09173F13E4C5 n4:271B5C37-363D-11E5-9242-09173F13E4C5 n4:271B5C38-363D-11E5-9242-09173F13E4C5 n4:271B5C35-363D-11E5-9242-09173F13E4C5 n4:271B5C36-363D-11E5-9242-09173F13E4C5 n4:271B5C4C-363D-11E5-9242-09173F13E4C5 n4:271B5C4D-363D-11E5-9242-09173F13E4C5 n4:271B5C39-363D-11E5-9242-09173F13E4C5 n4:271B5C3A-363D-11E5-9242-09173F13E4C5 n4:271B5C2F-363D-11E5-9242-09173F13E4C5 n4:271B5C30-363D-11E5-9242-09173F13E4C5 n4:271B5C2D-363D-11E5-9242-09173F13E4C5 n4:271B5C2E-363D-11E5-9242-09173F13E4C5 n4:271B5C33-363D-11E5-9242-09173F13E4C5 n4:271B5C34-363D-11E5-9242-09173F13E4C5 n4:271B5C31-363D-11E5-9242-09173F13E4C5 n4:271B5C32-363D-11E5-9242-09173F13E4C5 n4:271B5C2B-363D-11E5-9242-09173F13E4C5 n4:271B5C2C-363D-11E5-9242-09173F13E4C5 n4:271B5C58-363D-11E5-9242-09173F13E4C5 n4:271B5C59-363D-11E5-9242-09173F13E4C5 n4:271B5C56-363D-11E5-9242-09173F13E4C5 n4:271B5C57-363D-11E5-9242-09173F13E4C5 n4:271B5C4A-363D-11E5-9242-09173F13E4C5 n4:271B5C61-363D-11E5-9242-09173F13E4C5 n4:271B5C4B-363D-11E5-9242-09173F13E4C5 n4:271B5C5A-363D-11E5-9242-09173F13E4C5 n4:271B5C60-363D-11E5-9242-09173F13E4C5 n4:271B5C48-363D-11E5-9242-09173F13E4C5 n4:271B5C49-363D-11E5-9242-09173F13E4C5 n4:271B5C63-363D-11E5-9242-09173F13E4C5 n4:271B5C64-363D-11E5-9242-09173F13E4C5 n4:271B5C2A-363D-11E5-9242-09173F13E4C5 n4:271B5C62-363D-11E5-9242-09173F13E4C5 n4:271B5C3D-363D-11E5-9242-09173F13E4C5 n4:271B5C3E-363D-11E5-9242-09173F13E4C5 n4:271B5C3B-363D-11E5-9242-09173F13E4C5 n4:271B5C3C-363D-11E5-9242-09173F13E4C5 n4:271B5C41-363D-11E5-9242-09173F13E4C5 n4:271B5C42-363D-11E5-9242-09173F13E4C5 n4:271B5C29-363D-11E5-9242-09173F13E4C5 n4:271B5C3F-363D-11E5-9242-09173F13E4C5 n4:271B5C40-363D-11E5-9242-09173F13E4C5 n4:271B5C45-363D-11E5-9242-09173F13E4C5 n4:271B5C46-363D-11E5-9242-09173F13E4C5 n4:271B5C43-363D-11E5-9242-09173F13E4C5 n4:271B5C44-363D-11E5-9242-09173F13E4C5
n3:patent
n14:5854270 n14:5344658 n14:2205600
n3:synonym
Zofran odt
n3:toxicity
Low blood pressure and fainting, sudden blindness, severe constipation
n6:hasAHFSCode
n7:56-22-20
n3:foodInteraction
Take without regard to meals.
n3:proteinBinding
70%-76% (Plasma protein binding)
n3:salt
n3:synthesisReference
Peter Bod, Kalman Harsanyi, Ferenc Trischler, Eva Fekecs, Attila Csehi, Bela Hegedus, Eva Mersich nee Donat, Gyorgyi Szabo nee Komlosi, Erika Horvath nee Sziki, "Process for preparing ondansetron." U.S. Patent US5478949, issued September, 1990.
foaf:page
n9:ondansetron.htm n12:zof1501.shtml n13:ondansetron.html
n3:IUPAC-Name
n27:271B5CDC-363D-11E5-9242-09173F13E4C5
n3:InChI
n27:271B5CE2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n27:271B5CE1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n27:271B5CDE-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n27:271B5CDF-363D-11E5-9242-09173F13E4C5
n3:SMILES
n27:271B5CE0-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n27:271B5CDA-363D-11E5-9242-09173F13E4C5
n3:logP
n27:271B5CF2-363D-11E5-9242-09173F13E4C5 n27:271B5CD8-363D-11E5-9242-09173F13E4C5 n27:271B5CDB-363D-11E5-9242-09173F13E4C5
n3:logS
n27:271B5CD9-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n32:A04AA01
n3:H-Bond-Acceptor-Count
n27:271B5CE8-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n27:271B5CE9-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n27:271B5CE3-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n27:271B5CE4-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n27:271B5CE6-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n27:271B5CE5-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n27:271B5CE7-363D-11E5-9242-09173F13E4C5
n3:absorption
Ondansetron is well absorbed after oral administration and undergoes limited first-pass metabolism.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
99614-02-5
n3:category
n3:clearance
* 0.38 L/h/kg [Normal Adult Volunteers (19-40 yrs)] * 0.32 L/h/kg [Normal Adult Volunteers (61-74 yrs)] * 0.26 L/h/kg [Normal Adult Volunteers (>=75 yrs)]
n3:containedIn
n5:271B5CB1-363D-11E5-9242-09173F13E4C5 n5:271B5CBF-363D-11E5-9242-09173F13E4C5 n5:271B5CA4-363D-11E5-9242-09173F13E4C5 n5:271B5CA5-363D-11E5-9242-09173F13E4C5 n5:271B5CA2-363D-11E5-9242-09173F13E4C5 n5:271B5CA3-363D-11E5-9242-09173F13E4C5 n5:271B5CB0-363D-11E5-9242-09173F13E4C5 n5:271B5CA8-363D-11E5-9242-09173F13E4C5 n5:271B5CA6-363D-11E5-9242-09173F13E4C5 n5:271B5CA7-363D-11E5-9242-09173F13E4C5 n5:271B5C9C-363D-11E5-9242-09173F13E4C5 n5:271B5C9D-363D-11E5-9242-09173F13E4C5 n5:271B5C9A-363D-11E5-9242-09173F13E4C5 n5:271B5C9B-363D-11E5-9242-09173F13E4C5 n5:271B5C8B-363D-11E5-9242-09173F13E4C5 n5:271B5CA0-363D-11E5-9242-09173F13E4C5 n5:271B5C8C-363D-11E5-9242-09173F13E4C5 n5:271B5CA1-363D-11E5-9242-09173F13E4C5 n5:271B5C9E-363D-11E5-9242-09173F13E4C5 n5:271B5C9F-363D-11E5-9242-09173F13E4C5 n5:271B5C94-363D-11E5-9242-09173F13E4C5 n5:271B5C95-363D-11E5-9242-09173F13E4C5 n5:271B5C92-363D-11E5-9242-09173F13E4C5 n5:271B5C93-363D-11E5-9242-09173F13E4C5 n5:271B5C98-363D-11E5-9242-09173F13E4C5 n5:271B5C99-363D-11E5-9242-09173F13E4C5 n5:271B5C96-363D-11E5-9242-09173F13E4C5 n5:271B5C97-363D-11E5-9242-09173F13E4C5 n5:271B5C8D-363D-11E5-9242-09173F13E4C5 n5:271B5C90-363D-11E5-9242-09173F13E4C5 n5:271B5C91-363D-11E5-9242-09173F13E4C5 n5:271B5C8E-363D-11E5-9242-09173F13E4C5 n5:271B5C8F-363D-11E5-9242-09173F13E4C5 n5:271B5CC2-363D-11E5-9242-09173F13E4C5 n5:271B5CC0-363D-11E5-9242-09173F13E4C5 n5:271B5CC1-363D-11E5-9242-09173F13E4C5 n5:271B5CB2-363D-11E5-9242-09173F13E4C5 n5:271B5CB3-363D-11E5-9242-09173F13E4C5 n5:271B5CAE-363D-11E5-9242-09173F13E4C5 n5:271B5CAF-363D-11E5-9242-09173F13E4C5 n5:271B5CB6-363D-11E5-9242-09173F13E4C5 n5:271B5CB7-363D-11E5-9242-09173F13E4C5 n5:271B5CB4-363D-11E5-9242-09173F13E4C5 n5:271B5CB5-363D-11E5-9242-09173F13E4C5 n5:271B5CA9-363D-11E5-9242-09173F13E4C5 n5:271B5CAC-363D-11E5-9242-09173F13E4C5 n5:271B5CAD-363D-11E5-9242-09173F13E4C5 n5:271B5CAA-363D-11E5-9242-09173F13E4C5 n5:271B5CAB-363D-11E5-9242-09173F13E4C5 n5:271B5CB9-363D-11E5-9242-09173F13E4C5 n5:271B5CBA-363D-11E5-9242-09173F13E4C5 n5:271B5CB8-363D-11E5-9242-09173F13E4C5 n5:271B5CBD-363D-11E5-9242-09173F13E4C5 n5:271B5CBE-363D-11E5-9242-09173F13E4C5 n5:271B5CBB-363D-11E5-9242-09173F13E4C5 n5:271B5CBC-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n27:271B5CEE-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n27:271B5CF0-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n27:271B5CF1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n27:271B5CED-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n27:271B5CEC-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n27:271B5CEF-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n27:271B5CDD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n27:271B5CEA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n27:271B5CEB-363D-11E5-9242-09173F13E4C5